

Index

Abnormal Involuntary Movement Scale (AIMS), 7, 198	cerebral venous thrombosis (CVT), 146–47	neurostimulators, 64–66
action potential, 55–57	prevention, 147	patient programmers, 68
adverse effects. <i>See also</i> troubleshooting	troubleshooting, 147	quadripolar leads, 66–67
avoidance of, 54	clinician programmer, 68	implant surgery, 1–2
dystonia patients, 114–15	cognitive impairment	indications, 2
essential tremor patients, 80–81	Parkinson’s disease, 9–10, 84–85	medication adjustment, 169
OCD patients, 134	assessment, 9–10	neurostimulator type, 19
subthalamic nucleus stimulation, 97, 102–4	STN stimulation effects, 104	neurotransmitter effects, 54
amplitude	Cognitive–Behavioral Treatment History Form, 229	outcomes. <i>See</i> outcome assessment
adjustment, 69	complications. <i>See</i> adverse effects; troubleshooting	overview, 1
setting, 73, 76	computed tomography (CT), 46	patient expectations, 19, 185. <i>See also</i> patient education
dystonia patients, 111	CT-guided lead implantation surgery, 48–49	troubleshooting, 167
essential tremor patients, 79	versus MRI-guided surgery, 49–51	rough approximation of effective DBS, 54–55
Parkinson’s disease patients, 91, 94	postoperative, 40	safety, 62
anterior capsulotomy, 125	Parkinson’s disease, 90	success factors, 2–3
anterior cingulotomy, 125	preoperative, 43–45	surgical risk, 19
anterior nucleus of the thalamus, 119	confusion, postoperative, 148, 160	treatment approach, 3
Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy (SANTE) trial, 119–20	conjugate ocular deviation, 103	upper age limit, 11
antibiotics, 149	constant-current neurostimulators, 58–59	U-shaped response, 62
prophylactic, 149	comparisons, 59	delusions, Parkinson’s disease, 10
anxiety, 160	constant-voltage neurostimulators, 58–59	dementia, Parkinson’s disease, 9
apathy, 160	comparisons, 59	assessment, 9–10
apraxia of eyelid opening (ALO), 158–60	Core Assessment Program for the Surgical Interventional Therapies in Parkinson’s Disease (CAPSIT-PD), 9	depolarization blockade, 57
ataxia, 157		depression, 124
autonomic symptoms, Parkinson’s disease, 11		apathy relationship, 160
awake surgery		major depressive disorder (MDD), 126
challenges with, 45–46		Parkinson’s disease, 10
Parkinson’s disease patients, 12		STN stimulation and, 104
		diplopia, 158
basal ganglia, 31–32	deep brain stimulation (DBS), 1, 31, 53–54, 108. <i>See also</i> lead implantation; patient selection; <i>specific conditions</i>	dopamine agonist withdrawal syndrome (DAWS), 104
battery failure, 153	adjustability, 68–70	dopamine dysregulation syndrome (DDS), 88
battery status check, 75–76	amplitude, 69	dopaminergic responsiveness, 8–9
Beck Depression Inventory (BDI), 10	electrode configuration, 59–60, 69	dopa-responsive dystonia, 17
bladder function, 162	pulse width, 69	drooling, 162
blepharospasm, 102	rate, 53, 60–62, 69	dual-channel neurostimulators, 65–66
brain shift, 46	as a brain pacemaker, 32	dysarthria, 156–57, 164
Burke–Fahn–Marsden Dystonia Rating Scale (BFMDRS), 17, 113, 143, 216	clinical care implications, 62–63	dyskinesia, 157
	electronics of, 57–59	dysphagia, 162–63
	fine control, 60	dysphonia, 157
	hardware components, 64–68	dystonia, 15–19
	clinical programmer, 68	classification, 16
	extensions, 67	deep brain stimulation, 17–19, 108
		active electrode choice, 109–10
cardiovascular reflexes, 161–62		adverse effects, 114–15
cefazolin, prophylactic, 149		

Index

- dystonia (cont.)
 counseling patients on expected outcome, 18–19
 electrode configuration, 110
 follow-up programming, 112–13
 initial programming, 109
 predictive factors, 17–18
 stimulation parameters, 110–12
 target selection, 18, 108
 troubleshooting, 113–14
 definition, 15
 diagnosis clarification, 16–17
 disability assessment, 17
 documentation, 17
 neuropsychological and psychiatric assessments, 18
 pharmacological treatment status, 17
 Dystonia Study Group (DSG) scale, 113
 dystonic storm, 165
- electrical current, 58
 electrode configuration, 59–60, 69
 electromotive force (EMF), 58
 epilepsy, 2, 118, 122–23
 deep brain stimulation, 119
 hippocampal stimulation, 121–22
 Responsive Neurostimulation (RNS) trial, 121–22
 SANTE trial, 119–20
 neurostimulation for
 pharmacoresistant epilepsy, 119
 resective surgery, 118–19
 essential tremor, 13–15, 77–78
 certainty of diagnosis, 13–14
 deep brain stimulation, 15, 77
 adverse effects, 80–81
 clinical outcome assessment, 139
 data collection before
 programming, 77–79
 follow-up, 82
 patient instructions, 82
 patient programming, 79–81
 quality of life outcome assessment, 140
 target selection, 15
 test stimulation, 38
 unilateral versus bilateral treatment, 15
 Vim DBS, 77
 medical treatment, 77
 medication adjustments, 82
 treatment status, 14
 severity and related disability, 8
 type of intervention, 15
 EuroQol (EQ-5D), 139
- evaluation protocol. *See* program implementation
 eye movement abnormalities, 158
- Fahn–Tolosa–Marin Tremor Rating Scale, 8, 77, 143, 213
 falls, 103
 family physician role, 184
 Florida Surgical Questionnaire for Parkinson's Disease (FLASQ-PD), 167
 fluoroscopy, 46
 follow-up visits, 74–76
 duration, 75
 dystonia patients, 112–13
 essential tremor patients, 82
 interval history data, 75
 medication state, 75
 OCD patients, 133–34
 patient education, 76, 188
 physical exam, 75
 programming, 75–76, 188
 timing, 75
 what to bring, 75
 freezing of gait, 6, 103
- gait impairment, 157
 Geriatric Depression Scale, 10, 212
 globus pallidus internus (GPi), 12–13, 18, 32, *See also* GPi DBS
 anatomy, 108
 boundary determination, 35–37
 lead placement, 40
 GPi DBS. *See also* globus pallidus internus (GPi)
 dystonia, 108
 active electrode choice, 109
 adverse effects, 114
 follow-up programming, 112–13
 stimulation rate, 112
 neuropsychological and neuropsychiatric outcomes, 140
 Parkinson's disease, 84, 88–89, 94–97
 clinical effects, 85
 clinical outcomes assessment, 138–39
 delayed stimulation and medication adjustment, 97
 efficacy on drug-induced dyskinesia determination, 97
 efficacy on off-period parkinsonism determination, 94–97
 programming algorithm, 94
 programming data sheet, 221, 224
 troubleshooting, 164–65
 dysarthria/hypophonia, 164
 muscle contraction, 164
- status dystonicus, 165
 visual phenomena, 164
- hallucinations, 160
 Parkinson's disease, 10
 Hamilton Depression Rating Scale, 10
 health-related quality of life (HRQL), 139
 Parkinson's disease-specific scales, 139
 hemiballismus, 157
 hippocampal stimulation, epilepsy, 121–22
 hyperdopaminergic behavioral syndrome, 104
 hyperpolarization, 56
 hypersexuality, 164
 hypodopaminergic behavioral syndrome, 103
 hypomania, 160
 hypophonia, 157, 164
- image-guided surgery, 46, 51
 comparison of methods, 49–51
 CT-guided, 48–51
 MRI-guided, 46–51
 imaging
 intraoperative, 46
 postoperative, 40
 Parkinson's disease, 90
 preoperative, 43–45
 impedance, 58
 checking, 72, 75
 impulse control disorders (ICD), 88, 103
 impulsive–compulsive disorder (ICD) postoperative, 160
 infection, postoperative, 149–50
 prevention, 149
 troubleshooting, 149–50
 informed consent, 130
 initial visit, 70–74
 choice of first side, 71
 documentation, 70–71
 duration, 70
 explanation of the process, 71–72
 interval history data, 71
 medication state, 70
 participants, 70
 patient education, 73–74, 188
 programming, 72–73, 187–88
 sign/symptom selection for assessment, 71
 surgical and imaging data, 70
 surgical exam, 71
 timing, 70
 interdisciplinary approach, 143
 troubleshooting, 166–67
 internist role, 184

Index

- intracerebral hemorrhage (ICH),
 144–46
 prevention, 144–46
 troubleshooting, 146
- lead break, 151–52
- lead implantation, 33, 43, *See also*
 microelectrode recording
 (MER)
 anatomical targeting, 33
 awake surgery challenges, 45–46
 image-guided, 46, 51
 comparison of methods, 49–51
 CT-guided, 48–51
 MRI-guided, 46–51
 intraoperative imaging, 46
 intraoperative test stimulation,
 37–40
 mapping of lead position, 40
 OCD patients, 130–31
 pitfalls and sources of error, 40
 postoperative imaging, 40
 Parkinson's disease, 90
 preoperative imaging, 43–45
 suboptimal lead placement, 148–49
 prevention, 148
 troubleshooting, 149
- lead migration, 152
- levodopa responsiveness, 8–9
- magnetic resonance imaging (MRI)
 intraoperative, 46
 MRI-guided lead implantation
 surgery, 46–48
 versus CT-guided surgery, 49–51
 postoperative, 40
 Parkinson's disease, 90
 preoperative, 43–45
- major depressive disorder (MDD), 126
- Mattis Dementia Rating Scale
 (MDRS), 10
- medical evaluation, 187
- Medical Outcome Study Short
 Form-36 (SF-36), 139
- membrane potential, 56
- mesial temporal lobe epilepsy
 (MTLE), 118
- microelectrode recording (MER),
 33–37
 adverse effects testing, 37
 anatomical boundary
 determination, 35–37, 43
 sensorimotor region mapping,
 34–37
- mild cognitive impairment (MCI),
 Parkinson's disease, 9
 assessment, 9–10
- Modified Antidepressant Treatment
 History Form, 225
- Montgomery and Asberg Depression
 Rating Scale (MADRS), 10
- Montreal Cognitive Assessment Test –
 English, 211
- motor diary, 192
- movement disorder neurologist role,
 183
 initial screening evaluation, 185
 movement disorders, 32, *See also*
specific disorders
- muscle contraction, 155, 157, 164
- neuropsychological evaluation, 186
- neuropsychologist role, 183–84
- neurostimulators, 66
 comparison of types, 59
 constant-current, 58–59
 constant-voltage, 58–59
 dual-channel, 65–66
 failure, 153
 malfunction, 153
 migration, 153
 pain/discomfort over, 154
 single-channel, 65
- neurosurgeon role, 183
- neurosurgical evaluation, 186–87
- neurotransmitter role in DBS
 mechanism, 54
- Nottingham Health Profile (NHP),
 139
- nurse role, 183
- obsessive–compulsive disorder
 (OCD), 2, 124
 deep brain stimulation, 126
 adverse events, 134
 device programming, 131–35
 expected outcomes, 134–35
 follow-up visits, 133–34
 informed consent, 130
 lead implantation, 130–31
 parameter optimization,
 131–32
 patient selection, 126–29
 preoperative evaluation, 130
 surgical candidacy review,
 129–30
- occupational therapist role, 184
- Ohm's law, 58
- orbital undercuttings, 124
- outcome assessment
 clinical outcomes, 138–39
 neuropsychological/
 neuropsychiatric outcomes,
 143
 quality of life, 139–40
- pain over neurostimulator, 154
- paresthesia, 155, 157
- Parkinson's disease, 5–13, 32
 deep brain stimulation, 11–13,
 84–85
 awake versus asleep surgery, 12
 benefits of, 5–6
 clinical effects, 91
 clinical outcomes assessment,
 138–39
 delayed stimulation and
 medication adjustment, 94, 97
 device programming, 90–91
 early intervention, 84
 early motor complications study,
 12
 GPI stimulation, 94–97
 long-term patient management,
 102
 patient selection, 5–13, 167
 postoperative imaging, 90
 postoperative management,
 89–90
 PPN stimulation, 104–5
 preoperative management, 89
 previous PD surgery and, 12
 programming, 84
 quality of life outcome
 assessment, 139–41
 recording of clinical effects, 91
 simultaneous versus staged
 approach, 12
 site selection, 12–13, 88–89
 stimulation site impact on clinical
 effects, 85–88
 STN stimulation, 97–103
 test stimulation, 38
 unilateral versus bilateral
 treatment, 12
 upper age limit, 11
 Vim stimulation, 91–94
- dopaminergic responsiveness, 8–9
- evolving phenotype, 104
- idiopathic Parkinson's disease
 diagnosis, 6
- medical treatment status, 8, 85
 off- and on-medication
 evaluation, 186
- motor symptoms, 6–8
 dysphagia, 7
 freezing of gait, 6
 hypokinetic dysarthria, 7
 level of disability assessment, 7–8
 PD home motor diary, 7
 postural instability, 7
 symptoms which benefit from
 DBS, 7
- nonmotor symptoms, 9–11, 162
 autonomic symptoms, 11
 cognitive impairment, 9–10,
 84–85

Index

- Parkinson's disease (cont.)
 mood and psychotic symptoms, 10–11
 sensory symptoms, 11
 sleep disturbances, 11
 Parkinson's Disease Questionnaire (PDQ-39), 7, 209
 parkinsonism hyperpyrexia syndrome, 160
 patient education, 185
 educational session, 185–86
 essential tremor patients, 82
 follow-up visits, 76, 188
 initial visit, 73–74, 188
 safety, 74
 surgical procedure, 187
 patient programmers, 68, 73–74
 patient selection, 5
 dystonia, 15–19
 essential tremor, 13–15
 interdisciplinary and multidisciplinary consensus, 19–20
 Parkinson's disease, 5–13
 referral base establishment, 189–90
 troubleshooting, 166–67
 pedunculo pontine nucleus (PPN), 13,
 See also PPN DBS
 phosphenes, 164
 physical therapist role, 184
 physician assistant role, 183
 pneumonia, 148
 posterior thalamic area (PSA), 15
 postoperative care, 187
 Parkinson's disease, 89–90
 postural instability, 7, 103
 postoperative, 157
 PPN DBS, Parkinson's disease, 84, 94,
 104–5, *See also*
 pedunculo pontine nucleus (PPN)
 primidone, essential tremor treatment,
 14
 program implementation, 182–83
 DBS team, 183–84
 internist/family physician, 184
 movement disorder neurologist, 183
 neurosurgeon, 183
 nurse/physician assistant, 183
 physical, occupational and speech therapists, 184
 psychiatrist, 184
 psychologist/neuropsychologist, 183–84
 referring neurologist, 184
 educational session for patient and carers, 185–86
 evaluation protocol, 184–87
 initial screening by movement disorder neurologist, 185
 medical evaluation, 187
 neuropsychological evaluation, 186
 neurosurgical evaluation, 186–87
 off- and on-medication evaluation for PD patients, 186
 initial DBS device programming, 187–88
 physician time management, 188–89
 postoperative care, 187
 referral base establishment, 189–90
 subsequent device programming visits, 188
 programmers
 clinician programmer, 68
 patient programmers, 68, 73–74
 programming, 64
 amplitude setting, 73, 76
 battery status check, 75–76
 documentation of starting parameters, 75
 dystonia patients, 109
 follow-up programming, 112–13
 electrode selection, 72–73, 76
 essential tremor patients, 79–81
 follow-up visits, 75–76, 188
 impedance checking, 72, 75
 initial visit, 72–73, 187–88
 OCD patients, 131–35
 Parkinson's disease patients, 84, 90–91
 poor access to, 167–69
 usage data, 75
 propranolol, essential tremor treatment, 14
 psychiatric disorders. *See also*
 obsessive–compulsive disorder (OCD)
 deep brain stimulation and, 124
 historical overview, 124–26
 future directions, 135
 surgical candidacy review, 129–30
 psychiatric neurosurgery, 124
 psychiatrist role, 184
 psychologist role, 183–84
 psychosis, 160
 psychotic symptoms, Parkinson's disease, 10–11
 pulmonary embolism (PE), 147–48
 prevention, 147
 troubleshooting, 148
 pulse width adjustment, 69
 dystonia patients, 111
 essential tremor patients, 80
 Parkinson's disease patients, 90
 quality of life (QOL)
 definition, 139
 outcome assessment, 139–40
 Quality of Life in Essential Tremor Questionnaire (QUEST), 139
 Quality of Life Satisfaction – Deep Brain Stimulation (QLSm-DBS) Scale, 139
 rate adjustment, 53, 60–62, 69
 dystonia patients, 111–12
 essential tremor patients, 80
 Parkinson's disease patients, 90
 referral base establishment, 189–90
 referring neurologist role, 184
 Responsive Neurostimulation (RNS) trial, epilepsy, 119, 121–22
 responsive stimulation, 135
 restless legs syndrome (RLS), 103
 safety, 62
 patient education, 74
 Segawa's disease, 17
 seizures, postoperative, 147
 sensory symptoms, Parkinson's disease, 11
 seroma, 147
 sialorrhea, 163
 side effects. *See* adverse effects
 single-channel neurostimulators, 65
 skin erosion, 150–51
 sleep disturbances, Parkinson's disease, 11
 speech impairment, 157
 speech therapist role, 184
 status dystonicus, 165
 Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy (SANTE) trial, 119–20
 stimulation rate. *See* rate adjustment
 STN DBS. *See also* subthalamic nucleus (STN)
 adverse effects, 97, 102–4, 114
 dystonia, 108
 active electrode choice, 110
 stimulation rate, 112
 neuropsychological and neuropsychiatric outcomes, 143
 Parkinson's disease, 84–85, 88–89, 94, 97–103
 clinical effects, 85
 clinical outcomes assessment, 138–39
 cognitive and behavioral effects management, 103–4
 efficacy on drug-induced dyskinesia determination, 100–2

Index

- efficacy on off-period
 - parkinsonism determination, 97–100
- long-term patient management, 102
- motor symptoms management, 102–3
- programming algorithm, 97
- programming data sheet, 222
- troubleshooting, 157–64
 - apraxia of eyelid opening, 158–60
 - bladder function, 162
 - cardiovascular reflexes, 161–62
 - dysarthria/dysphonia/hypophonia, 157
 - dyskinesia, 157
 - dysphagia, 162–63
 - eye movement abnormalities, 158
 - gait impairment/postural instability, 157
 - hemiballismus, 157
 - hypersexuality, 164
 - muscle contraction, 157
 - neuropsychiatric complications, 160–61
 - paresthesia, 157
 - parkinsonism hyperpyrexia syndrome, 160
 - sialorrhea, 163
 - weight gain, 164
- subacute hippocampal stimulation (SAHCS), epilepsy, 121–22
- subcaudate tractotomy, 125
- subdural hematoma, 144–46
- substantia nigra pars reticulata (SNpr), 32
- subthalamic nucleus (STN), 12–13, 18, 32, 108, *See also* STN DBS
 - boundary determination, 35
 - lead placement, 38–39
 - sensorimotor circuits, 34
- surgical targeting, 135
- swallowing outcome, 162–63
- Systems Oscillators theory, 61
- tachycardia, 161
- tardive dystonia, 17
- team approach, 143
 - team member roles, 183–84
 - internist/family physician, 184
 - movement disorder neurologist, 183
 - neurosurgeon, 183
 - nurse/physician assistant, 183
 - physical, occupational and speech therapists, 184
 - psychiatrist, 184
 - psychologist/neuropsychologist, 183–84
 - referring neurologist, 184
- thalamotomy, essential tremor patients, 15
- The Essential Tremor Rating Assessment Scale, 14
- tolerance, 169–70
- Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS), 17, 113, 218
- total electrical energy delivered (TEED), 62
- Tourette syndrome, 151
- tremor, 77, *See also* essential tremor management, 82
- troubleshooting, 143–70
 - device-related issues, 149–54
 - battery/neurostimulator failure, 153
 - infection, 149–50
 - lead migration, 152
 - lead or wire break, 151–52
 - neurostimulator malfunction, 153
 - neurostimulator migration, 153
 - pain/discomfort over neurostimulator, 154
 - skin erosion, 150–51
 - disease progression, 166
 - GPI DBS, 164–65
 - medication adjustment, 169
 - poor access to programming, 167–69
 - poor candidate selection, 166–67
 - stimulation-related issues, 154
 - STN DBS, 157–64
 - surgery-related complications, 143–49
 - cerebral venous bleeding/infarction, 146–47
 - confusion, 148
 - intracerebral hemorrhage (ICH), 144–46
 - pneumonia, 148
 - pulmonary embolism, 147–48
 - seizure, 147
 - seroma, 147
 - suboptimal lead placement, 148–49
 - tolerance and loss of benefit, 169–70
 - unrealistic patient expectations, 167
 - Vim DBS, 154–57
- Twiddler syndrome, 151, 153
- Unified Dyskinesia Rating Scale (UDysRS), 7, 200
- Unified Dystonia Rating Scale (UDRS), 113
- Unified Parkinson's Disease Rating Scale (UPDRS), 7, 143, 193
 - MDS-UPDRS, 8
 - outcomes assessment, 138
 - motor subscale, 8
- urinary function, 162
- usage data, 75
- U-shaped response, 62
- vagus nerve stimulation (VNS), epilepsy, 119
- vancomycin hydrochloride, prophylactic, 149
- ventral capsule/ventral striatum (VC/VS), 125
 - VC/VS DBS, 126, 130, 134
 - adverse effects, 134
- ventral intermediate nucleus (Vim), 15, *See also* Vim DBS
 - boundary determination, 37
 - lead placement, 40
- Vim DBS. *See also* ventral intermediate nucleus (Vim)
 - essential tremor, 77
 - Parkinson's disease, 84, 91–94
 - clinical effects, 85
 - delayed stimulation and medication adjustment, 94
 - efficacy on drug-induced dyskinesia determination, 93
 - efficacy on tremor determination, 91–93
 - programming algorithm, 91
 - programming data sheet, 223
 - troubleshooting, 154–57
 - dysarthria, 156
 - muscle contraction, 155
 - paresthesia, 155
 - postural instability/ataxia, 157
 - weight gain, 164
 - wire break, 151–52